Families Hit Back At GSK'S Zofran Fraud Dismissal Bid

Law360, New York (January 4, 2017, 2:14 PM EST) -- Plaintiffs in a multidistrict litigation against GlaxoSmithKline PLC told a Massachusetts federal court Tuesday that they adequately set out off-label fraud claims in master complaints linking the anti-nausea drug Zofran to birth defects.

Although the master complaints lack granular detail about the alleged fraud, they lay out exactly what is needed at this stage in the MDL, which involves hundreds of people claiming their babies were injured or died as a result of prenatal exposure to the drug, according to the parents' opposition brief.

The filing came in response to GSK's argument that the fraud claims should be dismissed outright for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!